Phase Ib Study of Hemay181 Given by Intravenous Infusion for Patients Aged 18 to 75 With Advanced Solid Tumors Who Have Not Responded to Standard Treatments

What this Trial Is About

Researchers are evaluating the preliminary anti-tumor effects and safety of Hemay181 in adults with advanced solid tumors who have not responded to standard treatments or have no effective standard therapy available. This open-label Phase I clinical study focuses on patients with measurable lesions that can be assessed using CT or MRI scans. The study aims to measure how well Hemay181 works by monitoring the time until tumor progression or death. Participants receive Hemay181 as an intravenous infusion once every three weeks during each treatment cycle. The study does not include a placebo group and is designed to observe the effects and safety of this drug over time. The treatment period continues until the patient experiences disease progression or death, with assessments lasting up to 100 months. During the study, participants will have regular evaluations including imaging scans to track tumor size and laboratory tests to monitor safety. Researchers will follow patients closely from the start of treatment until progression or death, with a focus on both efficacy and safety indicators. The total duration of participation varies depending on individual response and disease progression.

A Clinical Study Evaluating the Preliminary Anti-tumor Efficacy and Safety of Hemay181